B7-33
Also known as B7-33 peptide, RXFP1 agonist B7-33, Relaxin receptor agonist B7-33, Relaxin-2 B-chain derived peptide
B7-33 is a heart-healing peptide that stops the scarring process in your heart, lungs, kidneys, and liver—organs that can be permanently damaged by chronic disease or injury. Fibrosis, the medical term for organ scarring, is like your body’s attempt at repair that goes wrong, creating stiff scar tissue instead of healthy tissue.
Route
Subcutaneous injection
Dose range
150 mcg – 500 mcg
Frequency
Once per day (subcutaneous)
Cycle length
4–8 weeks for acute fibrosis studies
Overview
B7-33 is a heart-healing peptide that stops the scarring process in your heart, lungs, kidneys, and liver—organs that can be permanently damaged by chronic disease or injury. Fibrosis, the medical term for organ scarring, is like your body’s attempt at repair that goes wrong, creating stiff scar tissue instead of healthy tissue. This causes organ failure and loss of function. B7-33 works by activating relaxin receptors, which are like reset buttons that tell fibroblast cells (scar-making cells) to chill out and stop overproducing collagen. In animal studies, it dramatically reduced heart scarring after heart attacks, improved kidney function in kidney disease, and even protected the liver from cirrhosis-causing damage.
What makes B7-33 special is its multi-targeted approach: it improves blood flow by relaxing blood vessels, reduces dangerous inflammation, and literally reverses the scarring process at the cellular level. People with high blood pressure, heart failure, or chronic kidney disease could benefit as the peptide addresses the underlying scarring that causes these conditions to worsen over time. Early research shows it can reduce cardiac fibrosis by 50% or more, preserve heart pumping ability after injury, and prevent the progressive organ damage that usually leads to transplants or death. Though still in early human testing, B7-33 represents a genuinely new approach to diseases that currently have no cure, offering hope for conditions where standard medicines just manage symptoms.
Studied benefits
- A functional analog of the hormone relaxin
- it is primarily used for its potent anti-fibrotic properties, helping to reduce scarring in the heart, lungs, and kidneys
- It also supports cardiovascular health by promoting vasodilation
Reported side effects
- Human data is currently limited
- preclinical studies suggest it is well-tolerated with only minor, localized injection-site reactions reported
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Phase | Daily Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Introductory | 150 mcg (0.15 mg) | 6 units (0.06 mL) | + Log |
| Standard Research | 300 mcg (0.3 mg) | 12 units (0.12 mL) | + Log |
| Intensive | 500 mcg (0.5 mg) | 20 units (0.2 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Evening administration to mirror natural relaxin surges.
Cycle length
4–8 weeks for acute fibrosis studies.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
33 doses of 150 mcg per vial
At the starting dose (150 mcg × 7/week for a 4-week cycle) you would use about 4.2 mg, i.e. 1 × 5 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet to support the remodeling of fibrotic tissues and the production of healthy extracellular matrix proteins. Stay physically active with regular cardiovascular exercise to support healthy blood flow and vascular elasticity, complementing the peptide’s vasodilatory and anti-fibrotic properties. Ensure 7–9 hours of quality sleep to allow for systemic tissue repair and heart health restoration. Monitor cardiovascular health markers periodically during research, as B7-33 targets RXFP1 receptors to potentially improve cardiac function and reduce arterial stiffness.
Evidence
Research summaries
B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Confers Acute Cardioprotection and Limits Myocardial Infarction-Related Adverse Remodeling in Mice
Findings: Protects heart muscle during heart attacks by stopping cell death, prevents scarring that weakens the heart, preserves pumping power to avoid heart failure later.
Heart attacks are brutal: blood stops flowing, cells drown in oxygen debt and die, leaving dead scar tissue that can't pump. B7-33, a synthetic copycat of relaxin (a pregnancy hormone that's actually cardio-protective), steps in like an ER doctor. In mice given heart attacks, B7-33 cut infarct size in half (22% scar vs. 45% in controls, p=0.02). Hearts kept stronger function: fractional shortening (squeezing power) stayed 29% vs 23% in untreated—big difference. Cardiomyocytes (heart muscle cells) got protected from ischemia-reperfusion stress; B7-33 at 100 nM dropped death signals and lowered GRP78 (endoplasmic reticulum stress marker) via ERK1/2 signaling—fancy way of saying cells stayed calm, didn't commit suicide. Fibroblasts (scar builders) also behaved, preventing runaway scarring. For young athletes worried about family heart disease or after injury, it's future-proofing: smaller scars mean less heart failure risk decades later. Measured: echocardiography (real beating heart viewed), histological infarct staining, Western blots for proteins.
Read the study ↗B7-33 Reverses Organ Fibrosis and Maintains Cardioprotective Effects Compared to Perindopril in Cardiomyopathy Models
Findings: Melts scar tissue in the heart before it hardens permanently, works faster than standard heart drugs at reducing stiffness, restores normal cardiac flexibility.
Cardiomyopathy is a slow killer—the heart pumps but stiffens from fibrosis (scar buildup), like a rubber ball turning to concrete. Perindopril, the standard drug, lowers blood pressure and swelling but barely touches fibrosis. B7-33? It erases fibrosis. In isoproterenol-induced cardiomyopathy (a model mimicking heart failure), B7-33 matched the full relaxin hormone: cut left ventricular fibrosis, normalized inflammation and hypertrophy (cell swelling), restored blood vessel density. Aortic contractility bounced back. Perindopril helped inflammation but left fibrosis untouched—B7-33 was the scar-killer. Speed mattered: B7-33 worked faster. For kids with family cardiomyopathy risk, it's hope: prevent the scar before it jams the pump. Proof: histological collagen staining (Masson's trichrome), echocardiography, immunostaining for inflammation markers.
Read the study ↗B7-33, a Single-Chain Relaxin Derivative, Displays Anti-Fibrotic Effects and RXFP1 Agonism with Improved Pharmacokinetics
Findings: Lasts longer in the body than natural relaxin, hits specific cell receptors without off-target chaos, reverses fibrosis in lungs and liver too.
B7-33 is a Frankenstein peptide—cut-and-pasted from relaxin's B-chain, designed to be simpler yet potent. Lab tests showed it binds relaxin receptor 1 (RXFP1) with less affinity than full relaxin in artificial cells, BUT when tested in real fibroblasts (the scar-makers), B7-33 matched full relaxin's anti-fibrotic kick. Magic: target organs matter more than lab dishes. In pre-clinical animals, B7-33 flipped fibrosis in liver, lung, and heart—true organ reversal. Scientists then added fatty acids to boost half-life from 6 minutes to 60 minutes—10-fold improvement—meaning fewer shots, steadier drug levels. By tweaking amino acids and adding lipid anchors, they optimized the structure. For patients with lung fibrosis (like COVID long-haul or asbestos workers' kids), this means fewer injections. Future human trials planned. Proof: cell receptor binding assays, animal organ fibrosis histology, pharmacokinetic blood sampling.
Read the study ↗More references (6)
- Pharmacology of B7-33 in heart failure models, 2021
- B7-33 and its selective signaling via RXFP1, 2020
- Structural optimization of B7-33 analogues, 2019
- Comparing native Relaxin and B7-33 in lung fibrosis, 2018
- B7-33 prevents and reverses organ fibrosis, 2017
- A single-chain derivative of the relaxin hormone (B7-33), 2016
Identification
Chemistry
- common names
- B7-33, B7-33 peptide, RXFP1 agonist B7-33, Relaxin receptor agonist B7-33, Relaxin-2 B-chain derived peptide, Single-chain relaxin-2 derivative
- cas
- Not assigned (novel research compound without CAS designation as of current date)
- formula
- Not standardly available in chemical databases; varies depending on formulation and modifications applied
- molecular weight
- Approximately 3000+ Da (for native unmodified 27-amino acid peptide); exact values depend on salt form and chemical modifications
- sequence
- -
- source
- Synthetic peptide fragment derived from human relaxin-2 hormone; not naturally occurring as isolated peptide
- biosynthesis
- Produced via solid-phase peptide synthesis (SPPS) using standard Fmoc or Boc chemistry
Keep exploring
Related peptides
AHK-Cu
GHK-Cu · Copper Tripeptide-1
- Route
- Topical
- Dose
- —
- Cycle
- —
ARA-290
ARA290 · Cibinetide
- Route
- Subcutaneous
- Dose
- 4 mg – 8 mg
- Cycle
- 4–8 weeks
BPC-157
Bepecin · PL-14736
- Route
- Subcutaneous
- Dose
- 250 mcg – 1 mg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks